Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ankara University
Interferon in combination therapy reduces hepatitis B YMDD mutant formation
June 15th, 2005
Interferon in combination therapy reduces hepatitis B YMDD mutant formation. "To determine whether combination treatment of hepatitis B virus (HBV) e antigen HBeAg- chronic hepatitis B is beneficial we studied 78 patients with HBeAg-, HBV DNA-positive chronic hepatitis B who were randomized to lamivudine, 100 mg, qd, for 12 months or lamivudine - interferon (9 MU, t.i.w.) in combination. In the combination arm, 2 months of lamivudine treatment preceded 10 months of combination treatment," scientists in Turkey report. "Biochemical, virologic and histologic responses were assessed at the end of treatment, after 6 and a median 27 months of drug-free...
Source: Physician Law Weekly (2005-06-15)
|
